evoleas
evoleas is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at evoleas.
Frequently Asked Questions
Who founded evoleas?
evoleas was founded by Nick Adams (Founder and CTO).
evoleas is a company.
Key people at evoleas.
evoleas was founded by Nick Adams (Founder and CTO).
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company specializing in the cash-pay aesthetic market, building a portfolio of consumer brands focused on medical aesthetics.[1][2] Its flagship product, Jeuveau®, is a proprietary neurotoxin (purified botulinum toxin type A) used to temporarily improve moderate to severe frown lines (glabellar lines) in adults, with sales in the U.S. and Europe, plus service revenue from Canadian distribution partners.[1][2] The company recently agreed to exclusively distribute Evolysse™, a line of five dermal fillers in late-stage development, targeting the $19B global medical aesthetics market—where neurotoxins and fillers represent nearly half—and an underpenetrated segment among 53M U.S. millennial and younger women, projected to grow 10% annually through 2028.[1]
Evolus serves physicians and consumers in the self-pay market via a customer-centric model and innovative digital platform, addressing aesthetic needs outside insurance-covered procedures.[1][2] It solves penetration gaps in a fast-growing sector by offering breakthrough products like Jeuveau, with growth momentum from expanding its portfolio and market presence.[1]
Evolus was founded in November 2012 by Scott Cannizzaro and is headquartered in Newport Beach, California.[3] The company emerged to capitalize on the burgeoning cash-pay aesthetics space, launching its first commercial product, Jeuveau, as a proprietary 900 kilodalton botulinum toxin type A formulation.[2] Early traction built around Jeuveau's U.S. and European rollout, supported by a unique business model emphasizing direct physician engagement and digital tools, setting the stage for portfolio expansion into dermal fillers like Evolysse.[1][2]
Evolus rides the wave of the exploding medical aesthetics market, fueled by rising consumer demand for non-invasive, cash-pay beauty treatments amid social media influence and millennial adoption.[1] Timing aligns with a projected 10% annual TAM growth through 2028, as aesthetic neurotoxins remain underpenetrated (low usage among 53M U.S. young women), bolstered by market forces like premiumization of self-care and digital personalization.[1] The company influences the ecosystem by innovating in biotech formulations and distribution, challenging incumbents like Botox through physician-focused models and portfolio diversification into fillers, fostering competition and accessibility in a sector blending medtech, consumer goods, and e-commerce platforms.[1][2]
Evolus is poised for accelerated growth via Evolysse launch and Jeuveau expansion, potentially capturing more of the $19B aesthetics market as millennial penetration rises.[1] Trends like AI-driven personalization in beauty tech and global cash-pay shifts will shape its path, with influence evolving through deeper digital integration and international scaling. This positions Evolus as a nimble challenger in performance beauty, building from Jeuveau's foundation toward a dominant aesthetic portfolio.[1][2]
Key people at evoleas.
evoleas was founded by Nick Adams (Founder and CTO).
